266
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee
S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N
Engl J Med 366:1190–1199
Martinel Lamas DJ, Rivera ES, Medina VA (2015) Histamine H4 receptor: insights into a potential
therapeutic target in breast cancer. Front Biosci (Scholar Edition) 7:1–9
Martorana G, Casa A, Oliva L, Orlando A, Cottone M (2001) Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant
Crohn’s disease and fistulas. Recenti Prog Med 92:451–455
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435
Milligan CE, Prevette D, Yaginuma H, Homma S, Cardwell C, Fritz LC, Tomaselli KJ, Oppenheim
RW, Schwartz LM (1995) Peptide inhibitors of the ICE protease family arrest programmed cell
death of motoneurons in vivo and in vitro. Neuron 15:385–393
Mollnes TE, Kirschfink M (2006) Strategies of therapeutic complement inhibition. Mol Immunol
43:107–121
Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G (2006) Effects of a leukotriene receptor
antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin
Immunol 118:347–353
Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, Crossman DC (2005)
Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary
artery model. Cardiovasc Res 68:493–501
Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174
Mosesson MW, Siebenlist KR, Meh DA (2001) The structure and biological features of fibrinogen
and fibrin. Ann N Y Acad Sci 936:11–30
Navab M, Gharavi N, Watson AD (2008) Inflammation and metabolic disorders. Curr Opin Clin
Nutr Metab Care 11:459–464
Ni J, Shu YY, Zhu YN, Fu YF, Tang W, Zhong XG, Wang H, Yang YF, Ren J, Wang MW, Zuo
JP (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through
modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol
186:94–103
Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y,
Takeuchi M, Shibanuma T, Isomura Y (1999) Peptide based interleukin-1β-converting enzyme
(ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the
ICE-inhibitor complex. Chem Pharm Bull (Tokyo) 47:11–21
Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause
heterogeneous dysfunction and damage. Curr Opin Neurol 16:259–265
Parker CW (1982) Leukotrienes: their metabolism, structure, and role in allergic responses. Adv
Prostaglandin Thromboxane Leukot Res 9:115–126
Patel AM, Moreland LW (2010) Interleukin-6 inhibition for treatment of rheumatoid arthritis: a
review of tocilizumab therapy. Drug Design Develop Ther 4:263–278
Perricone C, De Carolis C, Giacomelli R, Greco E, Cipriani P, Ballanti E, Novelli L, Perricone R
(2011) Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol 24:63–68
Petering H, Kohl J, Weyergraf A, Dulkys Y, Kimmig D, Smolarski R, Kapp A, Elsner J (2000)
Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the
native complement component C3a. J Immunol 164:3783–3789
Piatti G, Ceriotti L, Cavallaro G, Ambrosetti U, Mantovani M, Pistone A, Centanni S (2003)
Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 47:541–547
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands
BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405
Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19:345–355
B.C. Bhavya and M. Haridas
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee
S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N
Engl J Med 366:1190–1199
Martinel Lamas DJ, Rivera ES, Medina VA (2015) Histamine H4 receptor: insights into a potential
therapeutic target in breast cancer. Front Biosci (Scholar Edition) 7:1–9
Martorana G, Casa A, Oliva L, Orlando A, Cottone M (2001) Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant
Crohn’s disease and fistulas. Recenti Prog Med 92:451–455
Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435
Milligan CE, Prevette D, Yaginuma H, Homma S, Cardwell C, Fritz LC, Tomaselli KJ, Oppenheim
RW, Schwartz LM (1995) Peptide inhibitors of the ICE protease family arrest programmed cell
death of motoneurons in vivo and in vitro. Neuron 15:385–393
Mollnes TE, Kirschfink M (2006) Strategies of therapeutic complement inhibition. Mol Immunol
43:107–121
Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G (2006) Effects of a leukotriene receptor
antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin
Immunol 118:347–353
Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, Crossman DC (2005)
Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary
artery model. Cardiovasc Res 68:493–501
Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155–174
Mosesson MW, Siebenlist KR, Meh DA (2001) The structure and biological features of fibrinogen
and fibrin. Ann N Y Acad Sci 936:11–30
Navab M, Gharavi N, Watson AD (2008) Inflammation and metabolic disorders. Curr Opin Clin
Nutr Metab Care 11:459–464
Ni J, Shu YY, Zhu YN, Fu YF, Tang W, Zhong XG, Wang H, Yang YF, Ren J, Wang MW, Zuo
JP (2007) COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through
modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol
186:94–103
Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y,
Takeuchi M, Shibanuma T, Isomura Y (1999) Peptide based interleukin-1β-converting enzyme
(ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the
ICE-inhibitor complex. Chem Pharm Bull (Tokyo) 47:11–21
Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause
heterogeneous dysfunction and damage. Curr Opin Neurol 16:259–265
Parker CW (1982) Leukotrienes: their metabolism, structure, and role in allergic responses. Adv
Prostaglandin Thromboxane Leukot Res 9:115–126
Patel AM, Moreland LW (2010) Interleukin-6 inhibition for treatment of rheumatoid arthritis: a
review of tocilizumab therapy. Drug Design Develop Ther 4:263–278
Perricone C, De Carolis C, Giacomelli R, Greco E, Cipriani P, Ballanti E, Novelli L, Perricone R
(2011) Inhibition of the complement system by glutathione: molecular mechanisms and potential therapeutic implications. Int J Immunopathol Pharmacol 24:63–68
Petering H, Kohl J, Weyergraf A, Dulkys Y, Kimmig D, Smolarski R, Kapp A, Elsner J (2000)
Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the
native complement component C3a. J Immunol 164:3783–3789
Piatti G, Ceriotti L, Cavallaro G, Ambrosetti U, Mantovani M, Pistone A, Centanni S (2003)
Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 47:541–547
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands
BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405
Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19:345–355
B.C. Bhavya and M. Haridas